Summary Objectives: The ß-D-glucan assay (BDG) has been added to the EORTC/MSG criteria for the diagnosis of invasive fungal infections (IFI), but data from pediatric populations is scarce. The aim of this study was to evaluate performance of BDG in a cohort of hematooncological children with hematological malignancy at risk for IFI. Methods: 113 patients were included through an 18-month period. In addition to routine IFI screening, BDG was assayed once a week. IFIs were classified using EORTC/MSG criteria Pediatrics; Hematological malignancy without including the BDG results. Performances were assessed after a ROC analysis for optimization and multivariate analysis to detect the causes of false positivity. Results: 8 proven and 4 probable IFIs, and 7 possible IFIs were diagnosed in 9 and 7 patients, respectively. Sensitivity and specificity increased from 75% and 56% to 100% and 91.1%, respectively when considering the whole population and patients not having received any antifungals prior to the test. Multivariate analysis revealed that being younger than 7, severe colitis/mucositis, recent administration of polyvalent immunoglobulins and digestive colonization with Enterococcus sp were independent risk factors for false positivity. Conclusions: BDG is a valuable test to detect IFI in pediatric patients not previously treated with antifungals and to detect the occurrence of chronic infection.
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Introduction
Patients suffering from hematological malignancy are considered a population at high risk of developing invasive fungal infections (IFI). Nevertheless, epidemiological data in the particular setting of pediatrics is still limited. In a recent study including 244 high-risk children (acute leukemia, stem cell transplant), 55 patients (22.5%) developed a probable or proven IFI, consisting predominantly of invasive candidiasis (IC) (42%), followed by proven and probable invasive mold infections (33%). 1 It is well known that these infections are typically associated with high mortality rates, 38%, in the above study. This poor prognosis is partly due to the weak performance of the currently available diagnostic instruments, highlighting the requirement for developing fungal biomarker tests. 2 Indeed, conventional diagnostic methods are both poorly sensitive and require a period of incubation, leading to a delay in initiating an adequate antifungal therapy. Currently, specific biomarker commercial kits are available to diagnose invasive candidiasis, cryptococcosis and aspergillosis and the European Conference on Infections in Leukaemia ECIL has recently proposed recommendations for their use. 3 In addition to these specific tests, the b D-glucan (BDG) assay is becoming widely used for diagnosing IFI in various clinical contexts, including hematology, 4,5 solid organ transplantation 6 and intensive care unit. 7 BDG is a cell wall polysaccharide produced by a wide range of fungi and can be detected in the patient's serum during the infectious process of IFI. Preliminary data led the EORTCeMSG to include this test as part of the biological criteria used for the definition of IFI. 8 Recently, two studies focusing on hematologyeoncology adult patients reported a high sensitivity of 92e98% and a high specificity of 90e96% 9, 10 and the ECIL group confirmed that this test is be useful in diagnosing IFI in adult patients with leukemia. 11 On the contrary, data on the use of this test in pediatric populations remains very limited and led the fourth ECIL to conclude that no specific recommendation could be proposed for BDG in the diagnosis management of IFI in children. 12 The objective of this study was to evaluate the performances of BDG for the diagnosis of IFI in a hematologyeoncology cohort of pediatric patients. Furthermore, BDG kinetics during the course of IFIs, causes of false positive results, and the impact of the use of different cut-offs were analyzed.
Patients and methods

Patients
Patients of 18-year old or less, admitted in the hematologye oncology pediatric ward of our institution between 01/01/ 2013 to 30/06/2014 (18 months), with either Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia (AML), Burkitt leukemia, aplastic anemia, or admitted for an Autologous Hematopoietic Stem Cell Transplantation (AHSCT), were included. For each patient, demographic data (age, sex) and the type of hematological disease and other underlying conditions, were collected. Antifungal treatments received were also recorded, as well as the use of total parenteral and enteral nutrition, the administration of polyvalent immunoglobulins, and the occurrence and severity of colitis and/or mucositis, and of bacteremia and viral infections.
Antimicrobial management
The patients were handled according to the standard procedures of the ward. Systemic antifungal prophylaxis with 1 mg/kg/day micafungin was restricted to high-risk patients with expected prolonged neutropenia (>10 days) and the demonstration of Candida colonization in at least two stool samples. When fever occurred during the neutropenic phase, empiric antimicrobial therapy consisted in a combination of tazocillin (300 mg/kg/day of piperacillin, maximum 12 g/day) plus amikacin (15 mg/kg/day, maximum 1 g/injection). If fever persisted after 48 h, vancomycin (45 mg/kg/day, maximum 2 g/day) was added. According to the patient's condition, an empirical antifungal treatment was added between the 48th and the 96th hours of fever, or in the case of a new febrile episode after initial apyrexia, consisting in liposomal amphotericin B (3 mg/kg/ day), or caspofungin (70 mg/m2 day 1, then 50 mg/m2).
Diagnosis of IFIs
Routine procedures were applied for the diagnosis of IFIs. Multisite sampling for bacterial and fungal cultures was performed once a week during the neutropenic phase. All patients were routinely screened twice a week for Aspergillus galactomannan (GM) (Platelia Aspergillus, BioRad, Marnes la Coquette, France). A single positive GM test result (index ! 0.5) that was not associated with clinical symptoms and that did not lead to additional diagnostic procedures or change in antifungal medication, was considered as false positive. Candida Mannan antigenemia (Platelia Candida Antigen Plus, Biorad, Marnes la Coquette, France) were performed on demand according to the manufacturer' recommendations.
Specimens from samples targeted by symptoms were subject to direct examination to detect fungal elements and cultures on fungal media. Diagnosis of Pneumocystis pneumonia relied on the results of a home-made qPCR test. 13 During the neutropenic phase, a BDG seric assay was routinely performed once a week, according to the manufacturer's recommendations (Fungitell, Capecode, East Falmouth, USA). Determination was performed on a thermostat-controlled spectrophotometer (ELX 808, Biotek Instruments SAS, Colmar). All the sera were tested in duplicate, and the mean was assigned as the final result for the specimen. According to manufacturer's criteria, result was interpreted as negative for values lower than 60 pg/ml, as positive for values higher than 80 pg/ml, and as equivocal for values between 60 and 80 pg/ml. Values lower than 8 pg/ml and higher than 523 pg/ml were considered as being 8 and 523 pg/ml.
Performance evaluation and statistical analysis
To assess the performance of the BDG test, fungal infections were classified as proven, probable, and possible, according to the 2008 EORTC-MSG criteria without including the results of the BDG assays. 8 In addition, patients presenting small target abscesses in the liver and/or the spleen, which were detected using either ultrasonography or CT-scan, were considered as having possible or probable chronic disseminated infection if they had developed fungemia within the previous month or if they had positive mannan antigenemia assay, accordingly. Day 0 of the IFI diagnosis was defined either as the date of the first positive blood culture or as the date of the first positive GM seric assay or as the date when organ lesions were confirmed by imaging.
Sensibility, specificity, predictive positive value and predictive negative value were calculated using the cutoff levels recommended by the manufacturer in a first instance, i.e. negative assay for concentrations <60 pg/ml, positive when >80 pg/ml. Performance was also assessed using concentration rate highlighted by a ROC curve analysis. Finally, we compared the performance of the test when considering the first positive result of BDG and using two successive positive results.
Statistical analysis
Statistical analysis was performed using the Stata/IC 13.0 for Mac software (StataCorp, College Station, TX 77845, USA). For the descriptive analysis, the percentage rate was used to describe the characteristics of the population studied. A Chi-square test was used to test the associations between the variables. We also analyzed the causes of false positive results among the sera collected from patients considered free of IFI. In the univariate analysis, the dependent variable was the occurrence of a false positive result while the independent variables were gender, age class (0e6, 7e12, 13e18 years old), polyvalent immunoglobulin infusion in the previous 96 h, enteral nutrition, total parenteral nutrition, digestive colonization with Candida or Enterococcus, bacteremia, viral infection, severe digestive mucosal inflammation (colitis or mucositis grade III and IV). All variables associated with false positive BDG result with a p value < 0.25 in the univariate model were included in a binary logistic regression analysis. For each statistically significant factor, an odds ratio (OR) and 95% confidence interval (CI) were computed. The level of statistical significance was set as p < 0.05.
Ethical considerations
All samples and data were collected as part of routine diagnostic procedures. The study was retrospective and the results of the analysis did not influence the management of the patients. The database was declared to the French Data Protection Authority (Commission Nationale Informatique et Liberté) (no.1949795 v 0).
Results
Description of the pediatric population and IFIs diagnosed
Between January 2013 and June 2014, 126 children were enrolled in the study. Thirteen had a single BDG assay during their follow-up and were excluded from further analysis (Fig. 1) assays per patient (median: 10, range 2e22). Demographics charts and underlying diseases are summarized in Table 1 . Eight episodes of proven and 4 of probable IFI were diagnosed in 9 patients. Six patients presented fungemia due to Candida parapsilosis (n Z 2), Candida kefyr (n Z 1), Candida lusitaniae (n Z 1), Candida tropicalis (n Z 1), and Trichosporon asahii (n Z 1) (Table S1 , Supplementary data). Three of the patients, including the one with Trichosporon fungemia, developed probable chronic disseminated infection (CDI), which were considered independent episodes of infection. The other two presented Fusarium verticillioides invasive infection and pneumocystosis. There was also a case of probable chronic disseminated candidiasis. The overall incidence of probable and proven IFI was thus calculated at 10.6% in our cohort. In addition, 7 patients were classified as possible IFI (Table S1 ). Ninety-seven patients (617 sera) were considered free of IFI.
Performance of the b D-glucan assay
We first used the positivity criteria proposed by the manufacturer to evaluate the performance of the test. BDG glucan was found positive at the time of diagnosis in 6 cases among the 12 episodes of proven and probable infection (Fig. 2) . Among the 4 with probable CDI, 2 patients had highly positive BDG test, while the other 2 (including the patient infected with Trichosporon) remained negative. Among the 7 patients with possible IFI, 5 had positive BDG and consequently turned into probable Invasive Aspergillosis (IA) or probable CDI using the EORTC-MSG criteria, including the BDG test in the definition. Four of them had several consecutive positive tests (!3) supporting the diagnostic value of the test. On the other hand, 43 patients, considered free of infection, had at least one positive assay during their follow-up.
Taking into account these results and the cut-off levels recommended by the manufacturer (considering equivocal results as positive), the sensitivity for the detection of proven and probable episodes of IFI was calculated at 75% IC95 (69%e0.81%) with a specificity of 56% IC95 (50%e62%) ( Table 2 ). When considering two consecutive positive tests, the specificity increased to above 90% but sensitivity decreased to below 50%. We then hypothesized that previous antifungal therapy may negatively impact the assay. Indeed, among the 12 episodes of proven and probable infection, 5 of them that had been treated previously for more than 6 days with antifungal drugs, presented a negative BDG result at the time of the IFI diagnosis (Table S1 , Supplementary data). We thus compared ROC-curves obtained when using results of all sera sampled from patients free of IFI, and the first sample collected from patients with proven and probable IFI, either independently from any previous antifungal therapy, or limited to patients not having been treated for more than 6 days with antifungals. The area under the curve was at 0.8869 (p-value < 10-4) and 0.9584 (p-value < 0.0004), respectively, a difference at the limit of significance (p Z 0.06, Hanley method) (Fig. 2) . In the second case, a seric concentration of 75 pg/ml offered a sensitivity at 100% (IC95 47.82%e100.0%) and a specificity at 91.1% (IC95 88.57%e93.2%). The use of this cut-off level on a single sample gave the best performance of the test at the patient's level. In particular, the negative predictive value reached 96% and the accuracy 93%.
Potential factors leading to false positive results in the b D-glucan assay
Because specificity appeared limited, we tried to decipher the causes of false positive results by reviewing the data of the 613 BDG assays obtained from the 97 patients considered free of IFI. Using the cut-off value of 75 pg/ml (see above), we found, from the univariate analysis, that belonging to the youngest class of age, administration of polyvalent immunoglobulins within the 96 h preceding the BDG test, concomitant severe mucositis/colitis, ongoing enteral nutrition and Enterococcus colonization significantly increased the rate of false positive results (Table 3 ). In the multivariate analysis, belonging to the youngest class of age, digestive colonization with Enterococcus, severe colitis/mucositis and administration of polyvalent immunoglobulins were independent risk factors for false positive BDG results.
Timeline and kinetics of b -D-glucan in children with IFI Fig. 3 summarizes the time interval between day 0 of diagnosis of proven and probable IFI and the positivity of the BDG assays. Excluding the episodes of CDI complicating the course of fungemia, among the 7 episodes assessable, only one had a positive test before the diagnosis of IFI (episode 13). It should be further noted that this patient could not benefit from precocious imagery, and the precocity of positive BDG was somewhat relative.
Looking at the 5 patients with a positive test at the time of diagnosis and several tests performed during the follow-up, one can note that in 2 cases of probable non pre-treated chronic disseminated infections (cases 2.2 and 4.2) the BDG assay persisted to be positive, at a high level for weeks, while no clinical improvement occurred. On the contrary, BDG tests rapidly turned negative in 3 cases that had a favorable outcome under treatment (patients 7, 11, 12).
Discussion
The incidence of IFI has significantly increased over the last decades.
14 In addition, there is now a wider spectrum of etiologic agents causing these infections. 15 Indeed, some previously rare yeast species or filamentous fungi such as Fusarium, Scedosporium and Mucormycetes are now commonly reported as responsible for IFI, mainly in hematological wards. 16 This is illustrated in our analysis whereby the incidence of proven and probable IFI was of 10.6% but with no less than 7 different species recovered as causative agents.
It is largely admitted that the precocity of antifungal therapy is a key prognosis factor for these infections. Thus, a reliable and anticipated diagnosis is crucial. However, most often the clinical signs of IFI are nonspecific and the culture-based diagnostic tools have a limited sensitivity, which is even lower in hematologic patients who frequently receive prophylactic or empiric therapy. With the exception of those targeting cryptococcosis, the biomarkers available today for the diagnosis of IFI also exhibit limited performance. Notably, Aspergillus GM is subject to false positive and false negative results. 12, 17 Indeed, while still debated, the incidence of false-positive results could be more frequent in children as compared to adults. 18, 19 Thus the availability of any new biomarker assay, such as BDG, is considered as a potential breakthrough in the field of diagnosis.
The wide spectrum of targeted fungal pathogens with BDG is attractive regarding the increasing diversity of fungal pathogens. However, it should be remembered that mucormycetes and Cryptococcus neoformans do not produce enough BDG to be detected. It has also been suggested that some Candida species are less prone to produce BDG (Bougnoux ME personal communication). A low sensitivity for the BDG test, calculated at 50%, has already been mentioned for children suspected of IA. 20 However, our study points out that the limited sensitivity of the test may be due mainly to previous antifungal therapy. Indeed, after defining an appropriate cut-off level using a ROC analysis, we show that the sensitivity increases from 75% to 100% when we limit the study to patients who have been treated only for a limited period before the first BDG test. A number of patients treated with prolonged antifungal therapy prior to the BDG test received echinocandin antifungal drugs, which act through inhibition of BDG synthesis. This phenomenon has already been mentioned for both the detection of Aspergillus galactomannan antigen and the BDG test. 21, 22 In adult hematological populations, controversial results have been published, some reporting that pretreated patients have a greater chance of false negative results, 21, 23 while other not. 24 From these data, a recommendation could be to perform the BDG test before the initiation of any antifungal therapy. If a control is needed, it is best that it is performed before the 6th day of antifungal treatment.
In our study, 5 patients among 7 with a possible diagnosis of infection, turn into probable infection when integrating the BDG result in the definition criteria. This occurred in 2 patients with possible IA but with negative galactomannan antigen and 3 patients with possible CDI. While the positivity of the BDG test does not enable an etiologic diagnosis, this is an important result to comfort the fungal etiology and thus begin an antifungal rather than an antibacterial treatment.
In addition to its potential value in detecting IFI, the test appeared valuable in predicting the clinical outcome. Indeed, patients with an affected organ, notably in the case of CDI, had their BDG assays remaining high for weeks; whereas typically, patients with a single episode of candidemia rapidly cleared their seric BDG. Similar findings have been previously reported in adult patients. 25e27 Thus persistence of elevated BDG seric levels should prompt one to detect potential deep-seated infections.
However, the frequency of false positive results appeared as an important drawback of the BDG test. This limitation has already been mentioned by Badiee et al., who reported a 46% specificity in 62 pediatric patients suffering from hematological malignancy. 20 A better specificity at 78% was obtained when considering two successive samples in children undergoing allogeneic hematopoietic stem cell transplantation. 28 Among the cause of false positivity, previous administration of polyvalent immunoglobulins has been incriminated; as filtration on cellulose filters is part of their manufacturing process, that may release glucan components. 29 Intestinal barrier integrity also seems to be of major importance in false positives. Mucosal injury associated with severe mucositis/colitis due to 30 while Enterococcus digestive colonization and youngest age are known to increase the intestinal permeability. 31, 32 Thus, while the diagnosis of IFI in pediatric patients remains challenging, the availability of the BDG test offers a new possibility to detect these infections. Optimal sensitivity would be obtained for patients who have not been previously treated or at least treated for no more than 6 days. Careful interpretation is required in the case of a positive result as false positivity may be due to the infusion of polyvalent immunoglobulins or intestinal barrier damage. Further studies are required to confirm the usefulness of the test to guide maintenance therapy, as the kinetics of BDG seems to correlate with the clinical outcome.
